BaCkground: Mycosis fungoides is the most common form of primary cutaneous lymphoma, with an indolent, slowly progressive course and 88% five-year survival rate. The diagnosis is challenging, especially in the early stages, and usually relies on a good clinical-histopathological correlation. oBjeCtive: The aim was to establish the clinical and epidemiological profile of patients with early-stage mycosis fungoides. Methods: This was a retrospective cross-sectional observational study with an exploratory analysis. Outcome variables were disease progression and mycosis fungoides-related death. results: One hundred and two patients were included. The majority were white males, with a mean age of 55.6 years. Mean time from onset of lesions to diagnosis was 51.08 months. The majority of patients were classified as IB stage according to TNMB. Mean follow-up time was 7.85 years. Disease progression was seen in 29.4% of the patients. Death related to the disease occurred in 7.9% of patients. Plaque lesions, involvement of more than 10% of the body surface, altered lactate dehydrogenase and beta-2-microglobulin, and stage IB were significantly associated with disease progression, and altered lactate dehydrogenase and beta-2-microglobulin also correlated with higher frequency of deaths. study liMitations: Small sample and retrospective design. ConClusions: The clinical and epidemiological profile of patients with early-stage mycosis fungoides in our sample corroborates reports in the literature. Diagnostic delay in our series is also consistent with previous findings, but the rate of disease progression, despite treatment, was higher than reported in the literature.
INTRODUCTION
Primary cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of clonal T-cell lymphoproliferative disorders that affect the skin, without evidence of extracutaneous disease at the time of diagnosis. They account for 75-80% of all primary cutaneous lymphomas. Mycosis fungoides (MF) is the most prevalent CTCL, accounting for 50-65% of cases. [1] [2] [3] [4] [5] Even so, MF is a rare disease. The incidence in the United
States is approximately 0.3 to 1.02 new cases per 100,000 inhabitants/year. 3, 4 There are no data in Brazil on the incidence or prevalence of MF. The estimate for the year 2016 published by the Instituto Nacional de Câncer (INCA) for non-Hodgkin lymphomas (NHL) was 5,210 new cases in men and 5,030 in women, corresponding to an estimated risk of 5.27 new cases per 100,000 men and 4.88 per 100,000 women. 5, 6 Cutaneous lymphomas account for some 3.9% of all NHLs, and the majority of these are MF. 1 However, the INCA statistics make no distinction in relation to MF.
MF typically affects individuals in their late fifties and predominates in males, with a sex ratio between 1.6:1 and 2:1. The majority of patients are Caucasian. 1, 5 The etiology is still uncertain, but it appears to result from chronic antigenic stimulation leading to T-lymphocyte clonal expansion and infiltration of the skin. However, the determinant or participating factors in this antigenic stimulation are still unknown.
1,2
Diagnosis of MF is challenging, especially in the initial phases, and is usually based on clinical-pathological correlation. Immunophenotyping of the lymphoid infiltrate in the skin can provide additional information, and more recently, molecular methods have gained space in the research setting and are now available in clinical practice in large specialized centers.
1,2,7
Pimpinelli et al. proposed a diagnostic algorithm (Chart 1)
aimed at increasing the diagnostic accuracy, especially in early phases of the disease. 7 The algorithm is a score based on clinical, histopatho- 
Visceral involvement

M0
Absence of visceral involvement.
M1
Presence of visceral involvement, confirmed by histopathology. Must specify the organ involved.
Peripheral blood involvement
B0
Absence of peripheral blood involvement (less than or equal to 5% atypical lymphocytes or Sézary cells in peripheral blood). B0a (clone-negative)/B0b (clone-positive).
B1
Presence of more than 5% atypical lymphocytes, but without fullfilling criterion for B2. B1a (clone-negative)/ B1b (clone-positive).
B2
Presence of 1,000 or more Sézary cells per mm3 in peripheral blood, clone--positive. The analysis excluded patients with at least one of the following criteria:
Staging IIA or greater (disease with lymph node involvement, thus no longer limited to the skin);
Insufficient data on the patient's medical record;
Positive serologies for human T-cell lymphotropic viruses
Diagnosis of other associated lymphomas;
Follow-up time less than five years.
The dependent variables were:
Disease progression (upstaging), treated qualitatively, dichotomously, and nominally. Since the study included patients in stages IA or IB, disease progression was defined as patients that progressed to stage IIA or higher.
Death related to MF (either the lymphoma as the cause of death or deaths related to complications from the systemic therapies used). The variable MF-related death was also treated qualitatively, dichotomously, and nominally.
The independent variables were:
Gender, evaluated qualitatively, nominally, and dichotomously, considering the male or female sex of the study subject.
Skin color, described qualitatively and nominally as the self-declared color on the patient's medical file, as white, brown, or black.
Age at diagnosis, follow-up time, and time of evolution of the disease, all analyzed quantitatively, continuously, with the first two in years and the latter in months.
Macules/patches (alterations of the skin involving only the color, with no change in the relief or consistency) or plaques (elevated flat lesions greater than 1cm in diameter), 12 thus establishing qualitative and nominal evaluation. In the classification of this variable, there were more plaques than macules.
Topography of the lesions, differentiating between photoexposed and non-photoexposed areas, thus analyzed qualitatively, dichotomously, and nominally.
Number of lesions, assessed qualitatively, dichotomously, and nominally, differentiating between single and multiple lesions. Percentage of affected body surface, treated qualitatively and ordinally, as less than 10%, 10 to 80%, and more than 80%.
Presence of lymphadenomegaly, hepatomegaly, and splenomegaly, assessed qualitatively, dichotomously, and nominally, as absence or presence in the patient.
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Number of biopsies for the definitive diagnosis, treated as a discrete quantitative variable.
Peripheral eosinophilia and serum lactic dehydrogenase (LDH) and beta-2-microglobulin were also analyzed qualitatively, dichotomously, and nominally, and the results were thus classified as normal versus altered.
Imaging tests, when performed, were only differentiated as altered versus unaltered in relation to the lymphoma. Therefore, this was a qualitative, dichotomous, and nominal variable. 
RESULTS
From a total of 135 patients identified in the registry of the Photodermatology Sector, 102 were included in the study following application of the inclusion and exclusion criteria.
Among the 33 excluded patient charts, 17 showed missing data or insufficient follow-up time, ten had a different diagnosis (parapsoriasis, lymphomatoid papulosis, or GSS), and six had positive serologies for HTLV 1/2. Tables 1 to 6 show the results, subdivided in categories.
Clinical-epidemiological profile
There was a slight predominance of males (53.92%). Most patients in the sample were white (56.86%). Mean age at diagnosis was 55.16 years (standard deviation: 15.97), ranging from 10 to 83 years. Mean time from onset of lesions to diagnosis was 51.07 months (SD: 63.00), ranging from two to 360 months, as reported by the patients.
As for signs and symptoms, 54.91% of patients presented plaques as the predominant primary lesion. The absolute majority had multiple lesions of different sizes, except for one patient (0.98%) with a single lesion. Scaling was present in 61.76% of cases. Most patients had lesions predominantly on photoprotected areas, but in three patients (2.94%) the lesions predominated on photoexposed areas. In these, the lesions were more on the face, neck, and anterior thorax. In most patients (53.92%), between 10 and 80% of the 
Complementary tests and staging
All patients had undergone a complete blood count at the time diagnosis, allowing to assess the differential leukocyte count and presence or absence of eosinophilia. However, 13 patients had no record of serum LDH or beta-2-microglobulin.
All patients in the sample underwent chest and abdominal imaging at the time of diagnosis.
As for TNMB staging, 43.13% were classified as stage IA, and of these, 54.54% (23.52% of the total) were T1a, while 45.45% (19.60% 
Relationship between dependent and independent variables
Presence of plaque lesions, involvement of more than 10% of the body surface, altered LDH and beta-2-microglobulin, and stage IB were significantly associated with disease progression in the bivariate analysis. When related to death, only extent of the disease and altered LDH and beta-2-microglobulin remained significant.
The other target variables were not statistically significant (Table 6) . This finding also objectively reflects the difficulty in diagnosing MF, especially in the initial stages.
DISCUSSION
A multicenter retrospective study with more than 13 years of follow-up showed a mean delay of four to six years between onset of symptoms and diagnosis of MF, a finding corroborated by other studies. [13] [14] [15] In addition, diagnosis in the early stages is believed to depend on outpatient follow-up and multiple biopsies. 8 The majority of the patients presented some comorbidity, the most common of which was arterial hypertension. Among the hypertensive patients, 34.62% were in continuous use of hydrochlorothiazide. Continuous use of hydrochlorothiazide was found in 8.82% of the total sample, a higher rate than in the general population (5.8%). 17 We chose to highlight this finding, even though it was not a specific objective of the study, since Jahan-Tigh et al., in 2013, found a temporal relationship between MF and hydrochlorothiazide, besides the fact that some patients reported improvement after suspending the medication, suggesting that hydrochlorothiazide could be a trigger for MF in a small group of patients. 17 Further studies are necessary to verify the relationship between hydrochlorothiazide and MF.
Prior to the current study, the treatment protocol provided that all patients in the sample should be submitted to imaging tests The majority of patients in the current study were classified as IB (56.86%), with higher rates than described in the literature.
Mean follow-up time was 7.85 years. During follow-up, 29.40% of patients showed disease progression despite treatment.
This rate was higher than in previous studies. IB upstaging 4 and 25% encompassing stages IA and IB. 15 Sixteen patients (15.68%) evolved to death during follow-up.
Half of these (8 patients, thus 7.84% of the total) died due to disease progression of the lymphoma (4/8) or due directly to the chemotherapy (4/8). At five years, the percentage of deaths in the current study was lower than in the four cohorts cited previously. 4, 11, 13, 15 In addition to TNMB staging, knowledge of other factors can refine the prognostic workup of patients at increased risk of disease progression, which we find important, since even patients in the initial stage can evolve to advanced disease. Among the different target variables, the current study found that plaque lesions, involvement of more than 10% of body surface, altered LDH and beta-2-microglobulin, and stage IB were significantly related to disease progression, while altered LDH and beta-2-microglobulin also correlated with increased mortality. Studies have described the following factors with a clinical impact on prognosis: advanced age at diagnosis, male gender, plaque lesions, intense pruritis, lymphadenomegaly, peripheral eosinophilia, and elevated lactic dehydrogenase and beta-2-microglobulin. 
